Immunological and Pathological Peculiarity of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant
Author:
Affiliation:
1. Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon, South Korea
2. Department of Immunology, College of Medicine, Konkuk University, Chungju, South Korea
Abstract
Funder
National Research Council of Science and Technology
National Research Foundation
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology
Link
https://journals.asm.org/doi/pdf/10.1128/spectrum.02371-22
Reference69 articles.
1. WHO. 2020. WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed 3 February 2022.
2. WHO. 2022. WHO coronavirus (COVID-19) dashboard. https://covid19.who.int/. Accessed 3 February 2022.
3. The trinity of COVID-19: immunity, inflammation and intervention
4. COVID-19 and venous thromboembolism: current insights and prophylactic strategies
5. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Virus‐Induced Host Chemokine CCL2 in COVID‐19 Pathogenesis: Potential Prognostic Marker and Target of Anti‐Inflammatory Strategy;Reviews in Medical Virology;2024-08-27
2. Generation of a lethal mouse model expressing human ACE2 and TMPRSS2 for SARS-CoV-2 infection and pathogenesis;Experimental & Molecular Medicine;2024-05-31
3. The Role of Neutrophil in COVID-19 — Positive or Negative;Journal of Innate Immunity;2024-01-15
4. Age-dependent acquisition of pathogenicity by SARS-CoV-2 Omicron BA.5;Science Advances;2023-09-22
5. Role of CCL2/CCR2 axis in the pathogenesis of COVID-19 and possible Treatments: All options on the Table;International Immunopharmacology;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3